MedTrace Logo

Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI

NCT04298463 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2022-03-04

No results posted yet for this study

Summary

The aim of this study is to collect the data on the effectiveness of dalbavancin in terms of save of hospitalization days on patients treated between June 2017 and June 2019 in two countries (Italy and Greece) vs the other Standards of care of the same class (SoC; i.v. lipo and glycopeptides) in a real-life context.

Time to discharge from the start of therapy for ABSSSI in the hospital context will be assessed and all relevant data available on patient management, clinical, microbiological and safety outcomes during hospitalization and in the follow-up visits up to 30 days from discharge will be collected and evaluated.

Conditions

  • Acute Bacterial Skin and Skin Structure Infection

Interventions

DRUG

Xydalba

Drugs were administered i.v.

DRUG

vancomycin, teicoplanin or daptomycin

Drugs were administered i.v.

Sponsors & Collaborators

  • Hippocrates Research

    collaborator OTHER

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-18
Primary Completion
2021-05-19
Completion
2021-05-19

Countries

  • Greece
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298463 on ClinicalTrials.gov